검색어: neerutalitlus (에스토니아어 - 영어)

neerutalitlus
kidney function

neerutalitlus (clcr)
renal function (clcr)

kreatiniinisisalduse suurenemine (neerutalitlus)
high level of creatinine (kidney function)

kui teil on halvenenud neerutalitlus;
if you have poor kidney function;

- kui teie neerutalitlus on nõrgenenud.
- if you have poor kidney function.

kui teie neerutalitlus on tõsiselt kahjustatud,
if you have severely impaired renal function

- kui teie neerutalitlus on tõsiselt kahjustatud,
− if you have impaired liver function − if you have severely impaired renal function − if you have diabetes (see section 4) − if you are currently being treated for epilepsy dic

kui neerutalitlus vähenes, tõusis 5- fluorouratsiili püsikontsentratsiooni saadavus.
as renal function decreased, there was an increase in 5-fu steady state exposure.

kui teil on alanenud neerutalitlus, ei pruugi vistide teile sobida.
if you have decreased kidney function, vistide may not be appropriate therapy for you.

reproduction is authorised provided the source is acknowledged. mõõdukalt vähenenud neerutalitlus.
reproduction is authorised provided the source is acknowledged. bone metastases (when cancer has spread to the bone) if they have mild to moderately reduced kidney function.

enne desloratadine teva võtmist pidage nõu oma arsti või apteekriga. kui teie neerutalitlus on nõrgenenud.
talk to your doctor or pharmacist before taking desloratadine teva if you have poor kidney function.

eakatel patsientidel on suurema tõenäosusega kahjustatud neerutalitlus ja neil võib olla suurem risk vedelikumahu vähenemiseks.
elderly patients are more likely to have impaired renal function, and may be at a greater risk for volume depletion.

enne aeriuse võtmist pidage nõu oma arsti, apteekri või meditsiiniõega, kui teie neerutalitlus on nõrgenenud.
talk to your doctor, pharmacist or nurse before taking aerius: if you have poor kidney function.

monoklonaalsed antikehad teadaolevalt ei eritu neerude kaudu, mistõttu neerutalitlus ei mõjuta eeldatavasti alirokumabi farmakokineetikat.
since monoclonal antibodies are not known to be eliminated via renal pathways, renal function is not expected to impact the pharmacokinetics of alirocumab.

farmakokineetilisi uuringuid ei ole tehtud, kuid sugu või neerutalitlus ei mõjuta eelduste kohaselt coagadex’i farmakokineetilist profiili.
no pharmacokinetic studies have been conducted but there is no anticipated effect of gender or renal function on the pharmacokinetic profile of coagadex.

eakatel on suurema tõenäosusega neerutalitlus puudulik, mistõttu tuleb annuse valimisel olla ettevaatlik, samuti on soovitatav jälgida neerutalitlust.
because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it would be prudent to monitor renal function.

kuna ea tõustes neerutalitlus langeb, on see ainukeseks faktoriks, mida peaks silmas pidama (vt lõik neerukahjustus).
as renal function decreases with age this is the only factor to take into consideration (see renal impairment section).

kuna ea tõustes neerutalitlus langeb, on neerutalitlus ainukeseks faktoriks, mida peaks silmas pidama (vt lõik neerukahjustus).
as renal function decreases with age, renal function is the only factor to take into consideration (see renal impairment section).

siiski tuleb, nagu ka noorematel patsientidel, enne ribavirin mylani manustamist kindlaks määrata neerutalitlus (vt lõik 5.2).
however, as in younger patients, renal function must be determined prior to administration of ribavirin mylan (see section 5.2).

ravi tohib uuesti alustada vähemalt 48 tunni möödumisel ja ainult siis, kui neerutalitlus on analüüside põhjal hinnatud normaalseks (vt lõik 4.5).
48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.5).